Nuclera and Cambridge researchers produce GPCR structure in four days using cell-free technology

Nuclera and University of Cambridge researchers have demonstrated a four-day workflow for producing challenging membrane proteins for high-resolution structural analysis.

Nuclera and researchers at the University of Cambridge have demonstrated a rapid cell-free approach to producing G protein-coupled receptors (GPCRs) for high-resolution structural analysis, potentially addressing a longstanding challenge in drug discovery.

The collaboration produced a 3.38 Å resolution cryo-electron microscopy (cryo-EM) structure of an engineered human adenosine A2A receptor (A2AR) bound to an antagonist. The workflow took just four days from initial gene assembly to preparation of the sample for cryo-EM.

The findings, published as a preprint on bioRxiv, combine cell-free protein synthesis, Nuclera’s proprietary nanodisc technology and the University of Cambridge’s structural biology expertise.

GPCRs are an important class of drug targets, involved in signalling pathways associated with a wide range of diseases. However, studying their structures can be difficult because membrane proteins are often challenging to produce in sufficient quantities while maintaining their stability and correct folding.

Conventional production and purification methods can require extensive optimisation, creating a bottleneck in structural biology and the development of drugs targeting these proteins.

Cell-free production speeds up protein preparation

To address this challenge, the researchers combined Nuclera’s protein discovery system with cryo-EM expertise at the University of Cambridge’s Department of Biochemistry.

Using cell-free protein synthesis, the team screened different A2AR constructs against six lipid nanodisc conditions from Nuclera’s GPCR nanodisc panel to identify conditions that supported protein expression.

The highest-yielding conditions were then scaled up for purification and quality assessment before cryo-EM analysis. The resulting material enabled the researchers to determine the receptor’s structure at 3.38 Å resolution. Its architecture closely matched that of a reference receptor produced using conventional methods.

The four-day timeframe covered the process from gene assembly to cryo-EM sample preparation, rather than the entire process of structural determination.

Dr Dimitri Chirgadze, cryo-EM facility manager at the University of Cambridge’s Department of Biochemistry, said: “Advances in cryo-EM have transformed our ability to investigate protein structures, but obtaining suitable samples remains a major challenge, particularly for complex membrane proteins. This research demonstrates that rapid, cell-free protein production can deliver high-quality, active protein suitable for high-resolution structural analysis, potentially opening up opportunities to investigate a wider range of challenging drug targets.”

Wider potential for GPCR drug discovery

To explore whether the approach could be applied beyond A2AR, the researchers also produced and purified 12 additional GPCRs spanning Classes A, B and C.

The proteins included six orphan receptors, for which endogenous activating ligands have not been identified. The researchers assessed the additional proteins using fluorescence-detection size-exclusion chromatography (FSEC), providing evidence that the production workflow could be applied across different GPCR targets.

Although these additional receptors were not all structurally characterised in the reported work, their production and purification demonstrate the potential to extend the approach to further structural and biophysical investigations.

Dr Michael Chen, co-founder and chief scientific and business officer at Nuclera, said: “Access to membrane proteins remains a significant obstacle in drug discovery. By combining our cell-free protein synthesis and proprietary nanodisc technology with the University of Cambridge’s structural biology expertise, we have demonstrated a faster route to producing proteins suitable for high-resolution analysis. This represents an important step towards making difficult-to-study drug targets more accessible, with the potential to accelerate structural biology research and streamline future drug discovery.”

The research is available as a preprint on bioRxiv and will be presented at PEGS Europe on 19 November by Dr Audrey Dubourg, in a session titled From Gene to Grid in Four Days: A Cell-Free Route to GPCR Cryo-EM.

Nuclera is also planning a webinar with Chirgadze on 15 December to discuss the findings and their implications for GPCR structural biology.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox